[ad_1]
We live in interesting times, as Wegovy (semaglutide’s blockbuster weight loss injection) has been found to have beneficial effects beyond just weight loss. The current study showed that the drug can help people with diabetes deal with a common type of obesity-related heart failure.
This is good news for doctors and patients alike, because obese people have higher blood sugar levels, enlarged hearts, and an increased risk of heart failure.
Semaglutide has been making waves on the international stage since clinical trials were completed for both Ozempic as a diabetes treatment and Wigovy as a weight loss drug. A new study published in the New England Journal of Medicine reveals growing evidence of semaglutide’s effectiveness in addressing multiple health conditions. The latest research and trials show that these wonder drugs, called glucagon-like peptide 1 receptor agonists (GLP1 RA), not only control blood sugar levels, but also lower blood pressure and cholesterol. These slow the progression of chronic kidney disease and prevent death from related complications.
What new research shows
Obesity-related heart failure usually involves a condition in which the lower chambers of the heart pump less blood than the body needs. According to clinical reviews, it affects 32 million people worldwide, with an annual mortality rate of about 15%. People with type 2 diabetes have more severe heart failure than people without type 2 diabetes. However, patients who took Wegovy reported feeling less tired and swollen, had less shortness of breath, and were able to walk farther in six minutes than those who took a placebo.
What does this mean for treatment?
Cardiologists are now likely to prescribe Wegoby to patients with heart failure. So far, they have prescribed certain heart medications apart from lifestyle changes. American Heart Association (AHA) guidelines currently recommend SGLT2 inhibitors, drugs that lower blood sugar levels by preventing the kidneys from reabsorbing sugar produced by the body, for heart failure. Now this may change. Obesity is correlated not just with body weight but also with the metabolic state of the heart, and Wegovy appears to be addressing this complexity.
However, we need to test this drug in a large representative section of Indian participants to see if these findings apply to us as well. Given the high global demand, Wigobee is expected to be introduced in India by 2026, according to manufacturer Novo’s Nordisk.
What makes Wegovy special?
Until about 10 years ago, all weight loss drugs were found to have side effects and had to be stopped. This situation has changed with glucagon-like peptide 1 compounds such as liraglutide, lixisenatide, and exenatide. But it was semaglutide, sold as a WeGovy injection for obesity, that showed an unprecedented weight loss of about 10 to 15 percent in users. It has a dual benefit because it helps release insulin from the beta cells of the pancreas and suppresses glucagon, a hormone from the alpha cells of the pancreas that tends to raise blood sugar levels.
Wegovy helps reduce hunger by slowing the movement of food from the stomach to the small intestine. This will help you feel fuller, eat less, and control fatty liver.
It is administered as an injection of 2.4 mg per week.
[ad_2]
Source link